Real-World Data (RWD) is the raw material for generating Real-World Evidence, consisting of health information collected outside of traditional clinical trials. Understanding the various sources, specific strengths, and inherent limitations of RWD is a fundamental skill for evidence-based practice, as highlighted in the Principles of Evidence-Based Practice course. This quiz will focus specifically on the types of Real-World Data, the challenges of data quality, and the pharmacist’s role as both a user and generator of this crucial information.
1. Real-World Data (RWD) is best defined as:
- a. The conclusions drawn from a clinical study.
- b. Data relating to patient health status and/or the delivery of health care collected from sources outside of traditional clinical trials.
- c. Only data from randomized controlled trials.
- d. The statistical analysis plan for a research project.
Answer: b. Data relating to patient health status and/or the delivery of health care collected from sources outside of traditional clinical trials.
2. Which of the following is considered a primary source of Real-World Data?
- a. A published meta-analysis
- b. A clinical practice guideline
- c. Electronic Health Records (EHRs)
- d. A review article in a journal
Answer: c. Electronic Health Records (EHRs)
3. A major strength of using EHR data for research is that it:
- a. Is always perfectly clean and structured for analysis.
- b. Contains detailed, longitudinal clinical information like lab values and progress notes.
- c. Is free from any missing information.
- d. Captures patient experiences outside the healthcare system.
Answer: b. Contains detailed, longitudinal clinical information like lab values and progress notes.
4. What is a primary limitation of using medical claims and billing data as a source of RWD?
- a. The sample sizes are too small.
- b. It lacks detailed clinical information (e.g., severity of illness, lab results) because it is collected for billing purposes.
- c. It has no information on which drugs were dispensed.
- d. The data is not anonymous.
Answer: b. It lacks detailed clinical information (e.g., severity of illness, lab results) because it is collected for billing purposes.
5. Data collected from a patient’s smartphone app or fitness tracker is known as:
- a. Claims Data
- b. Registry Data
- c. Patient-Generated Health Data (PGHD)
- d. Electronic Health Record Data
Answer: c. Patient-Generated Health Data (PGHD)
6. The “Pharmacoepidemiology Study Designs” module, which forms the basis for using RWD, is part of which course?
- a. PHA5244 Principles of Evidence-Based Practice
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5787C Patient Care 5
Answer: a. PHA5244 Principles of Evidence-Based Practice
7. “Data reliability” in RWD refers to:
- a. The volume of the data available.
- b. The speed at which the data can be accessed.
- c. The accuracy and consistency of the data over time.
- d. The cost of acquiring the data.
Answer: c. The accuracy and consistency of the data over time.
8. When a pharmacist accurately documents a patient’s medication history during reconciliation, they are directly contributing to:
- a. The quality of their institution’s Real-World Data.
- b. A decrease in pharmacy profits.
- c. An increase in alert fatigue.
- d. The development of a new drug.
Answer: a. The quality of their institution’s Real-World Data.
9. A disease registry is a valuable source of RWD because it:
- a. Collects data on all patients in a hospital.
- b. Collects specific, uniform data on a population of patients with a particular condition.
- c. Is primarily used for billing.
- d. Contains no clinical information.
Answer: b. Collects specific, uniform data on a population of patients with a particular condition.
10. Real-World Evidence (RWE) is derived from the analysis of Real-World Data (RWD).
- a. True
- b. False
Answer: a. True
11. The appraisal of cohort studies, which often use RWD, is a “Transcending Concept” in the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
12. A researcher is using an EHR database. They find that patient weights are often missing or are not updated regularly. This is an example of what RWD challenge?
- a. Lack of generalizability
- b. Data completeness and quality issues
- c. Small sample size
- d. High cost
Answer: b. Data completeness and quality issues
13. “Structured data” (e.g., from dropdown menus, specific fields) is generally easier to analyze than “unstructured data” (e.g., free text in a progress note).
- a. True
- b. False
Answer: a. True
14. A pharmacist using the EHR to review a patient’s past lab trends to inform a dosing decision is an example of using RWD for:
- a. A population-level study.
- b. Individual patient care.
- c. A clinical trial.
- d. Billing purposes.
Answer: b. Individual patient care.
15. Evaluating relevant primary literature to answer drug information questions is a key objective for student pharmacists.
- a. True
- b. False
Answer: a. True
16. Which source of RWD would be best for determining the total cost of care for a specific disease?
- a. A patient registry
- b. An Electronic Health Record
- c. A patient’s fitness tracker
- d. An insurance claims database
Answer: d. An insurance claims database
17. The “Observational Studies” module is part of the EBP course.
- a. True
- b. False
Answer: a. True
18. What is a key limitation of using EHR data to study medication adherence?
- a. The EHR shows what was prescribed and dispensed, but not what the patient actually took.
- b. The EHR does not contain any medication information.
- c. The sample sizes are too small.
- d. The EHR is not electronic.
Answer: a. The EHR shows what was prescribed and dispensed, but not what the patient actually took.
19. “Data curation” is the process of:
- a. Deleting all old data.
- b. Organizing, cleaning, and validating data to make it suitable for analysis.
- c. Collecting new data only.
- d. Publishing the raw data.
Answer: b. Organizing, cleaning, and validating data to make it suitable for analysis.
20. An active learning session on EBP is part of which course?
- a. PHA5244 Principles of Evidence-Based Practice
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5787C Patient Care 5
Answer: a. PHA5244 Principles of Evidence-Based Practice
21. A major challenge in linking different sources of RWD (e.g., a patient’s EHR and their insurance claims) is:
- a. Data interoperability and patient privacy concerns.
- b. The data is always in the same format.
- c. There is no benefit to linking data.
- d. It is too easy to do.
Answer: a. Data interoperability and patient privacy concerns.
22. Which source of RWD is most likely to contain detailed clinical notes and physician rationale for treatment decisions?
- a. A medical claims database
- b. A patient-reported outcomes survey
- c. An Electronic Health Record (EHR)
- d. A wearable device
Answer: c. An Electronic Health Record (EHR)
23. The use of diagnostic codes (like ICD-10) in claims data is a form of:
- a. Unstructured data
- b. Structured data
- c. Free text data
- d. Inaccurate data
Answer: b. Structured data
24. An active learning session on appraising cohort studies is part of which course module?
- a. Module 5: Urological Disorders
- b. Module 1: Diabetes Mellitus
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 5: Urological Disorders
25. A pharmacist’s role in the ecosystem of Real-World Data is:
- a. Only as a consumer of the evidence generated from it.
- b. Only as a generator of data through documentation.
- c. As both a generator and a critical consumer of data and evidence.
- d. A pharmacist has no role.
Answer: c. As both a generator and a critical consumer of data and evidence.
26. The increasing use of EHRs has dramatically _______ the availability of RWD for research.
- a. decreased
- b. had no impact on
- c. increased
- d. eliminated
Answer: c. increased
27. A key question when using RWD is whether the data are “fit for purpose,” meaning:
- a. The data is expensive.
- b. The data is relevant and of sufficient quality to answer the specific research question.
- c. The data is easy to access.
- d. The data comes from a single source.
Answer: b. The data is relevant and of sufficient quality to answer the specific research question.
28. An active learning session on study designs is part of the EBP curriculum.
- a. True
- b. False
Answer: a. True
29. The data from a product registry for a new biologic agent would be considered:
- a. Real-World Data
- b. Phase I trial data
- c. Pre-clinical data
- d. Anecdotal data
Answer: a. Real-World Data
30. The “Introduction to study designs in pharmacoepidemiology” is a required reading in the EBP course.
- a. True
- b. False
Answer: a. True
31. Which of the following is a potential source of bias in a study using EHR data?
- a. Only sick patients have their labs drawn, leading to unrepresentative data.
- b. Some physicians document more thoroughly than others.
- c. A diagnosis may be listed on a problem list but may not be active.
- d. All of the above.
Answer: d. All of the above.
32. Using RWD allows researchers to study medication effects in a population that is typically more ____ than an RCT population.
- a. homogenous and healthy
- b. diverse and complex (with more comorbidities)
- c. small
- d. controlled
Answer: b. diverse and complex (with more comorbidities)
33. The principles of pharmacoepidemiology are foundational to understanding how to analyze RWD.
- a. True
- b. False
Answer: a. True
34. A study using RWD to compare two drugs is susceptible to confounding by indication.
- a. True
- b. False
Answer: a. True
35. A pharmacist accurately verifying a patient’s allergy list contributes to:
- a. Higher quality RWD and better functioning of clinical decision support systems.
- b. Alert fatigue.
- c. Increased healthcare costs.
- d. A slower dispensing process.
Answer: a. Higher quality RWD and better functioning of clinical decision support systems.
36. A limitation of using pharmacy claims data to measure adherence is that:
- a. It shows when a prescription was filled, but not if the patient actually took the medication.
- b. It is not accurate for dates.
- c. It does not include the name of the drug.
- d. It is too detailed.
Answer: a. It shows when a prescription was filled, but not if the patient actually took the new medication.
37. The term “data provenance” refers to:
- a. The process of analyzing data.
- b. The process of storing data.
- c. The metadata describing the origin, history, and movement of a piece of data.
- d. The cost of data.
Answer: c. The metadata describing the origin, history, and movement of a piece of data.
38. The “Experimental Studies” module is part of the EBP course.
- a. True
- b. False
Answer: a. True
39. A pharmacist using an EHR to identify all patients on a recently recalled medication is using RWD for what purpose?
- a. A clinical trial
- b. Public health surveillance and intervention
- c. Billing
- d. Marketing
Answer: b. Public health surveillance and intervention
40. An active learning session covering EBP is part of which course?
- a. PHA5244 Principles of Evidence-Based Practice
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5787C Patient Care 5
Answer: a. PHA5244 Principles of Evidence-Based Practice
41. The quality of RWD can be improved by:
- a. Using standardized terminologies (e.g., SNOMED CT, RxNorm).
- b. Minimizing the use of free-text fields.
- c. Training clinicians on proper documentation.
- d. All of the above.
Answer: d. All of the above.
42. Which of the following CANNOT be easily determined from most RWD sources?
- a. The date a prescription was dispensed.
- b. A patient’s diagnosis code.
- c. The patient’s underlying reason or motivation for being non-adherent.
- d. The patient’s age.
Answer: c. The patient’s underlying reason or motivation for being non-adherent.
43. A pharmacist’s ability to critically appraise all forms of evidence is a core professional competency.
- a. True
- b. False
Answer: a. True
44. “Big Data” in healthcare refers to:
- a. The large, complex datasets that constitute Real-World Data.
- b. The physical size of a hospital’s servers.
- c. A single clinical trial.
- d. The cost of medications.
Answer: a. The large, complex datasets that constitute Real-World Data.
45. Before using RWD for a research study, a researcher must:
- a. Obtain appropriate ethical and IRB approval.
- b. De-identify the data to protect patient privacy.
- c. Develop a clear study protocol.
- d. All of the above.
Answer: d. All of the above.
46. A major benefit of RWD is its ability to track drug safety issues:
- a. Only before a drug is approved.
- b. Over the long term, after a drug is on the market.
- c. Only in healthy volunteers.
- d. Only in a small number of patients.
Answer: b. Over the long term, after a drug is on the market.
47. A study on RWD is only as good as the quality of the data it uses.
- a. True
- b. False
Answer: a. True
48. An active learning session on study design is part of which course module?
- a. Module 2: Pharmacoepidemiology Study Designs
- b. Module 1: Formulating a Clinical Question
- c. Module 6: Summarizing the Evidence
- d. Module 3: Applying Biostatistics
Answer: a. Module 2: Pharmacoepidemiology Study Designs
49. The overall purpose of leveraging RWD is to:
- a. Replace randomized controlled trials.
- b. Supplement the evidence from RCTs to get a more complete picture of a drug’s effects.
- c. Make healthcare research more complicated.
- d. Increase the amount of data entry for clinicians.
Answer: b. Supplement the evidence from RCTs to get a more complete picture of a drug’s effects.
50. The ultimate reason for a pharmacist to understand RWD is to:
- a. Be a better consumer and contributor to health information for the benefit of patient care.
- b. Become a data scientist.
- c. Pass the EBP final exam.
- d. Design their own EHR system.
Answer: a. Be a better consumer and contributor to health information for the benefit of patient care.
